VXRT news

Vaxart stockholders rejected an advisory vote on executive compensation while ratifying auditor selection. The rejection of the say-on-pay proposal highlights investor concerns regarding executive compensation structures.

Vaxart reported top-line safety data for its Phase 2b oral COVID-19 vaccine, finding no vaccine-related serious adverse events or sustained Grade 3 adverse events. This positive result supports the oral pill candidate's development profile as efficacy data is still pending.

Vaxart and a group of stockholders agreed to a cooperation agreement ending a recent proxy contest. The group has withdrawn its director nominations for the 2026 annual meeting, which is expected to avert potential voting instability.

Vaxart received additional BARDA funding to advance COVID-19 vaccine data analysis. The release allows the company to report 12-month trial data.